Jump Financial LLC Has $1.42 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Jump Financial LLC trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 78.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 7,241 shares of the medical research company’s stock after selling 26,626 shares during the quarter. Jump Financial LLC’s holdings in IQVIA were worth $1,423,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Vanguard Group Inc. raised its position in IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares during the last quarter. Geode Capital Management LLC increased its position in IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after acquiring an additional 77,981 shares during the period. Invesco Ltd. grew its stake in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock worth $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after buying an additional 59,426 shares during the period. Finally, Cantillon Capital Management LLC raised its position in shares of IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock worth $406,018,000 after acquiring an additional 226,017 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IQV. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Finally, Barclays restated an “equal weight” rating and issued a $170.00 target price (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $241.50.

IQVIA Stock Performance

Shares of IQVIA stock opened at $143.66 on Friday. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The firm has a market capitalization of $25.33 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The business’s fifty day simple moving average is $176.42 and its 200 day simple moving average is $196.62. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.